- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01805778
Preventing Cardiac Sequelae in Pediatric Cancer Survivors (PCS2)
Novel Approaches to the Prediction, Diagnosis and Treatment of Cardiac Late Effects in Survivors of Childhood Cancer: A Multi-centre Observational Study
Study Overview
Status
Conditions
Detailed Description
This is a multi-centre observational cohort study that will be conducted at The Hospital for Sick Children (Toronto), Princess Margaret Hospital (Toronto), McMaster Children's Hospital (Hamilton), London Health Sciences Centre (London), The Children's Hospital of Eastern Ontario (Ottawa) and The Children's Hospital of Orange County (Orange County, California).
The study will address the current limitations in prediction and early diagnosis of anthracycline-induced heart disease. This will be accomplished by the following 3 collaborative cores:
Core 1 (Genomics) will focus on determining which children are most susceptible to treatment-related cardiac toxicity by assessing genes in pathways related to anthracycline absorption, distribution, metabolism, and excretion, as well identifying genes in pathways known to be important in the cardiac response to injury.
Core 2 (Biomarkers) will explore whether existing and novel biomarkers allow for more accurate diagnosis of acute and late treatment-related cardiac toxicity. The core will use a human stem cell platform for discovery of novel biomarkers of anthracycline cardiac damage that will be evaluated in our clinical cohort.
Core 3 (Cardiac imaging) will focus on the evaluation of new echocardiographic and CMR techniques aimed at early identification of cardiac damage after anthracycline exposure.
It will investigate whether changes in cardiac function immediately after anthracycline administration predict which patients will develop progressive cardiac disease over time, and it will explore disease progression through the longitudinal evaluation of innovative echocardiographic parameters of remodeling and dysfunction in CCS exposed to anthracyclines.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada
- McMaster Children's Hospital
-
London, Ontario, Canada
- London Health Sciences Centre
-
Ottawa, Ontario, Canada
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G1XE
- SickKids
-
Toronto, Ontario, Canada, M5T2M9
- Princess Margaret Hospital
-
-
-
-
California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
ACUTE COHORT:
Inclusion Criteria:
- Aged <18 years at time of cancer diagnosis
- Diagnosed with a new malignancy (patients with a history of a prior malignancy wlil be eligible if they have not received any anthracycline chemotherapy or chest radiation)
- Cancer treatment plan will require therapy with at least one dose of any anthracycline
- Planned to have all pre-anthracycline echocardiograms (ECHO) at the recruiting site
- Normal cardiac functioning prior to initiation of anthracycline therapy (LV EF > 55%)
- Patients who are uncooperative during the ECHO without sedation or anesthesia will be included in the study. However, these patients will only undergo clinically indicated echocardiograms, with no echocardiograms added for purely research purposes
- Provision of signed informed consent by the patient and/or patient's legal guardian
Exclusion Criteria:
- Patients who were previously treated with anthracycline chemotherapy or radiation to the chest.
- Significant congenital heart defects, including patients with any other congenital cardiac abnormality, except those with a patent foramen ovale or a small ASD. Patients with familial cardiomyopathies (hypertrophic, dilated and restrictive) will be excluded.
SURVIVOR COHORT:
Inclusion Criteria:
- Aged < 18 years at time of cancer diagnosis
- Previously diagnosed with cancer and currently in remission
- Patients whose prior treatment plan included therapy with at least one dose of any anthracycline
- Patients who completed their final dose of anthracycline at least 3 years ago
- Routinely followed at the recruiting site approximately ever 12 months
Exclusion Criteria
- Prior allogeneic stem cell transplant
- Significant congenital heart defects, including patients with any other congenital cardiac abnormality, except those with a patent foramen ovale or a small ASD. Patients with familial cardiomyopathies (hypertrophic, dilated and restrictive) will be excluded.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Acute Cohort
Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
|
Survivor Cohort
Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac Remodeling
Time Frame: one year after last dose of anthracycline therapy in Acute Cohort; anytime during 2 year follow up in Survivor Cohort
|
The presence of one or more of the following:
|
one year after last dose of anthracycline therapy in Acute Cohort; anytime during 2 year follow up in Survivor Cohort
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul C Nathan, M.D., The Hospital for Sick Children
- Principal Investigator: Mark Greenberg, M.D., The Hospital for Sick Children
- Principal Investigator: Seema Mital, M.D., The Hospital for Sick Children
- Principal Investigator: Luc Mertens, M.D., The Hospital for Sick Children
- Principal Investigator: Paul Kantor, M.D., University of Alberta/Stollery Children's Hospital
- Principal Investigator: Peter Liu, M.D., Ottawa Heart Institute
Publications and helpful links
General Publications
- Chaix MA, Parmar N, Kinnear C, Lafreniere-Roula M, Akinrinade O, Yao R, Miron A, Lam E, Meng G, Christie A, Manickaraj AK, Marjerrison S, Dillenburg R, Bassal M, Lougheed J, Zelcer S, Rosenberg H, Hodgson D, Sender L, Kantor P, Manlhiot C, Ellis J, Mertens L, Nathan PC, Mital S. Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors. JACC CardioOncol. 2020 Dec 15;2(5):690-706. doi: 10.1016/j.jaccao.2020.11.004. eCollection 2020 Dec.
- Skitch A, Mital S, Mertens L, Liu P, Kantor P, Grosse-Wortmann L, Manlhiot C, Greenberg M, Nathan PC. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer. 2017 Aug 3;17(1):519. doi: 10.1186/s12885-017-3505-0.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000032746
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anthracycline-induced Cardiotoxicity
-
Queen's University, BelfastActive, not recruitingAnthracycline Induced CardiotoxicityUnited Kingdom
-
TC Erciyes UniversityCompletedAnthracycline Induced CardiotoxicityTurkey
-
Texas Tech University Health Sciences CenterRecruitingAnthracycline Related Cardiotoxicity in Breast CancerUnited States
-
Fundación Centro Nacional de Investigaciones Cardiovasculares...European CommissionRecruitingLymphoma | Anthracycline-induced Cardiac ToxicityNetherlands, Spain, Denmark, Germany, France, Portugal
-
Stony Brook UniversityGilead SciencesUnknownHeart Failure | Breast Cancer | Biomarkers | Cardiotoxicity | Echocardiography | Anthracycline Induced CardiomyopathyUnited States
-
OnxeoCompletedAnthracycline ExtravasationDenmark
-
Kissei Pharmaceutical Co., Ltd.CompletedExtravasations of Anthracycline Anti-cancer AgentsJapan
-
Kansas State UniversityCompletedCancer Survivor With History of Anthracycline ChemotherapyUnited States
-
Yonsei UniversityRecruitingChemotherapy Induced CardiotoxicityKorea, Republic of
-
Zhejiang Cancer HospitalRecruitingCardiotoxicity Induced by Drug Therapy for Breast CancerChina